Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. In gene therapy, small stretches of deoxyribonucleic acid (DNA) called "anti-HIV genes" are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.

Official Title

A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells

Details

Keywords

HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Burkitt Lymphoma, Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease, Mantle-Cell Lymphoma, T-Cell Lymphoma, Lymphoma, Large-Cell, Immunoblastic, Recurrence, Cytarabine, Etoposide, Podophyllotoxin, Etoposide phosphate, Melphalan, Mechlorethamine, Carmustine, Nitrogen Mustard Compounds, Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Peripheral Blood Stem Cell Transplantation

Eligibility

Locations

  • UCSF Medical Center-Parnassus
    San Francisco California 94115 United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento California 95817 United States
  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • Memorial Sloan Kettering Cancer Center
    New York New York 10065 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AIDS Malignancy Consortium
ID
NCT02797470
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
About 11 people participating
Last Updated